RPTX: Repare Therapeutics, Inc. Price-to-Revenue Multiple

Symbol and logo of brand Repare Therapeutics, Inc. (RPTX)

This price/sales multiple chart illustrates the financial standing of Repare Therapeutics, which is systematically deploying its available capital toward targeted oncology programs. Successes in synthetic lethality and interest from pharmaceutical behemoths are driving business valuation growth. However, stringent patent restrictions and rigorous regulatory oversight create significant barriers. The current mark of 9.60 characterizes this company valuation parameter.

RPTX Repare Therapeutics Inc Market Cap to Revenue (07/04/2022 - 02/07/2026)

Analytical breakdowns for Repare Rx (RPTX)

- share price and consensus valuation forecast:
Price Performance Chart reparerx.com|RPTX - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Repare Rx|RPTX - Enterprise Value
- book capitalization data:
Net Asset Value per Share Repare Therapeutics|RPTX - Company Net Assets|Market Cap to Book Value Multiple reparerx.com|RPTX - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital Repare Therapeutics|RPTX - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Repare Therapeutics Inc|RPTX - Company Total Debt|Debt to Net Assets Ratio Repare Rx|RPTX - Company Long-Term Liabilities|Amount of Current Liabilities Repare Therapeutics|Intermediate Coverage Ratio reparerx.com
- earnings and multiples data:
RPTX - Net Profit|Expected Net Profit Repare Therapeutics|RPTX - Price to Earnings Ratio|Future Price to Earnings Multiple Repare Therapeutics, Inc.|RPTX - PEG Multiple|EV/EBITDA Multiple Repare Rx|RPTX - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Repare Therapeutics|RPTX - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months reparerx.com|RPTX - Earnings per share growth in current year|Expected earnings per share trend next year Repare Therapeutics
- sales revenue and business income indicators:
RPTX - Revenue and Sales Volume|Company Expected Sales Volume reparerx.com|RPTX - Price-to-Revenue Ratio|Future Price to Revenue Repare Rx
Summary company analytics:reparerx.com, RPTX
Mass-produced product of reparerx.com

Fundamental risks for Repare Therapeutics (RPTX) necessitate strict monitoring of the market capitalization to annual revenue ratio. For an R&D-phase biotech developing precision oncology, this metric reflects market expectations for future sales. The P/S value chronology demonstrates the cost of each unit of current revenue, making it possible to identify asset overvaluation. An analysis of the chart's extremes warns investors against buying at the peak of speculative demand.

Who Repare Therapeutics competes with

GMAB (genmab.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple EXEL (Exelixis)|Price-to-Revenue Multiple Nuvalent Inc|Kymera Therapeutics Inc - P/S Multiple|Price to Sales IDEAYA Corp|ELVN (Enliven Therapeutics) - Market Cap to Revenue|ORIC: Market Cap to Sales Volume|RLAY (Relay Therapeutics, Inc.) - P/S Multiple|Price to Sales Nurix Therapeutics Inc NRIX|P/S Multiple TYRA|Verastem Corp - Market Cap to Revenue Ratio|Monte Rosa Therapeutics - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CGEM|IMRX: Market Cap to Revenue|C4 Therapeutics Inc - Market Cap to Sales Volume|BDTX: P/S Multiple|PMV Pharmaceuticals, Inc - Market Capitalization-to-Revenue Ratio|KPTI (Karyopharm Therapeutics, Inc.) - P/S Multiple|Price to Sales Propanc Biopharma, Inc. PPCB|Price-to-Revenue Ratio Bio Green Med Solution (BGMS)|AADI (aadibio.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALRN (Aileron Therapeutics, Inc.)|P/S Multiple Blueprint Medicines Corp. BPMC|GLYC - Price-to-Revenue Ratio|Price-to-Sales Ratio SWTX